Fortis Healthcare FY26 Revenue at ₹9,128 Crore, Up 17.3%; Recommends ₹1 Dividend
Fortis Healthcare reported FY26 consolidated revenue of ₹9,128 crore, up 17.3%. The company recommended a ₹1 per share dividend. Hospital business revenue grew 19.1% to ₹7,773 crore, and diagnostics revenue was ₹1,355 crore. Consolidated profit after tax surged 31.5% to ₹1,064 crore. Management expects 15% revenue growth in FY27 for hospitals.
The announcement includes comprehensive financial results, strategic expansion plans, and dividend declaration, all of which are material information for investors and significantly impact the company's valuation and future prospects.
The company reported strong year-on-year growth in revenue, EBITDA, and profit after tax, along with a recommended dividend. Expansion plans and positive outlook for the diagnostic business also contribute to the positive sentiment.
Fortis Healthcare Limited announced its audited financial results for the quarter and financial year ended March 31, 2026, along with the transcript of the Investors/Analysts' meet held on May 25, 2026. The Board has recommended a dividend of ₹1 per share, representing 10% of the face value, for the fourth consecutive year.
For the financial year 2026, consolidated revenues grew by 17.3% to ₹9,128 crore. The hospital business revenue increased by 19.1% to ₹7,773 crore, while diagnostic business net revenues were ₹1,355 crore, a growth of 8%. Consolidated operating EBITDA rose by 31.3% to ₹2,085 crore, with margins improving to 22.8% from 20.4% in FY25. Consolidated profit after tax increased by 31.5% to ₹1,064 crore.
In Q4 FY26, consolidated revenues stood at ₹2,365 crore, a 17.8% increase over Q4 FY25. The hospital business grew 19% to ₹2,023 crore, and diagnostic business net revenue was ₹341 crore. Consolidated operating EBITDA margins were 22.5%, and profit after tax increased by 44.2% to ₹271 crore.
The company added approximately 800 beds through brownfield expansion and acquisitions, including People Tree Hospital in Bengaluru (125 beds), a hospital in Greater Noida (200 beds), and Shrimann Super specialty Hospital in Jalandhar (228 beds). A mental health facility, Adayu, was launched in Gurugram. Fortis plans to add around 1,800 beds through brownfield expansion over the next four years. Capital expenditure for FY26 was approximately ₹700 crore.
The Diagnostic business (Agilus) reported FY26 revenues of ₹1,527 crore, up 8.5%, with operating EBITDA margins at 23.6%. For Q4 FY26, revenues were ₹387 crore, an 11.1% year-on-year growth, with operating EBITDA margins at 22%. Agilus processed 40.8 million tests in FY26 and expanded its network with over 675 customer touchpoints.
Management discussed occupancy levels, the impact of onco drug capping, and future growth strategies. The company expects 15% plus revenue growth for the hospital business in FY27 with a 150 basis point margin improvement, and diagnostic business EBITDA margins between 23% to 24%. IHH, the parent company, plans to increase its stake to 50% with a potential equity infusion of ₹10,000 crore.
What to do with a filing like this
Fortis Healthcare Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Fortis Healthcare Limited. Read the original for the full detail.